Frederick G. Hayden mainly investigates Virology, Immunology, Virus, Orthomyxoviridae and Internal medicine. His Virology research is multidisciplinary, incorporating perspectives in Oseltamivir, Coronavirus and Microbiology. His Virus research focuses on Polymerase chain reaction and how it connects with Mutation.
His Internal medicine research integrates issues from Influenza a, Placebo and Surgery. His Placebo study incorporates themes from Oral administration, Influenzavirus, Gastroenterology, Adverse effect and Randomized controlled trial. The Neuraminidase study combines topics in areas such as Hemagglutinin, Influenzavirus B, Zanamivir and Neuraminidase inhibitor.
The scientist’s investigation covers issues in Virology, Immunology, Virus, Internal medicine and Rhinovirus. His research integrates issues of Oseltamivir, Pandemic and Microbiology in his study of Virology. His studies deal with areas such as Zanamivir and Neuraminidase as well as Oseltamivir.
His Immunology research includes themes of Respiratory system and Intensive care medicine. His work in Internal medicine addresses subjects such as Placebo, which are connected to disciplines such as Clinical trial. In Rhinovirus, Frederick G. Hayden works on issues like Common cold, which are connected to Anesthesia.
His scientific interests lie mostly in Internal medicine, Virology, Middle East respiratory syndrome, Intensive care medicine and Virus. His research on Internal medicine often connects related areas such as Placebo. His biological study spans a wide range of topics, including Severe acute respiratory syndrome coronavirus 2, Pandemic and Coronavirus disease 2019.
His Virus study combines topics from a wide range of disciplines, such as Host and H5N1 genetic structure. In his study, Drug development is strongly linked to Immunology, which falls under the umbrella field of Middle East respiratory syndrome coronavirus. As part of the same scientific family, Frederick G. Hayden usually focuses on Neuraminidase inhibitor, concentrating on Orthomyxoviridae and intersecting with Neuraminidase.
Middle East respiratory syndrome, Internal medicine, Immunology, Pneumonia and Retrospective cohort study are his primary areas of study. The concepts of his Internal medicine study are interwoven with issues in Placebo and Viral load. He has included themes like Middle East respiratory syndrome coronavirus and Intensive care in his Immunology study.
His study looks at the relationship between Pneumonia and topics such as Coronavirus, which overlap with Intensive care medicine, Respiratory system, Neuraminidase inhibitor, Oseltamivir and Severity of illness. His study with Antibody titer involves better knowledge in Virology. He is involved in the study of Virology that focuses on Outbreak in particular.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A novel coronavirus outbreak of global health concern.
Chen Wang;Peter W Horby;Frederick G Hayden;George F Gao.
The Lancet (2020)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Yeming Wang;Yeming Wang;Dingyu Zhang;Guanhua Du;Ronghui Du.
The Lancet (2020)
Avian Influenza A (H5N1) Infection in Humans
John H Beigel;Jeremy Farrar;Aye Maung Han;Frederick G Hayden.
The New England Journal of Medicine (2005)
Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection.
Edgar Bautista;Tawee Chotpitayasunondh;Zhancheng Gao.
The New England Journal of Medicine (2010)
Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza
John J. Treanor;Frederick G. Hayden;Peter S. Vrooman;Rick Barbarash.
The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in Children
Robert B. Belshe;Paul M. Mendelman;John Treanor;James King.
The New England Journal of Medicine (1998)
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
Maki Kiso;Keiko Mitamura;Yuko Sakai-Tagawa;Kyoko Shiraishi.
The Lancet (2004)
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections
Frederick G. Hayden;Albert D.M.E. Osterhaus;John J. Treanor;Douglas M. Fleming.
The New England Journal of Medicine (1997)
Influenza virus neuraminidase inhibitors
Larisa V Gubareva;Laurent Kaiser;Frederick G Hayden.
The Lancet (2000)
Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense.
F. G. Hayden;R. S. Fritz;M. C. Lobo;W. G. Alvord.
Journal of Clinical Investigation (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: